強直性脊椎炎治療市場規模、シェア、成長分析、治療タイプ別、薬剤タイプ別、エンドユーザー別、地域別- 産業予測、2025～2032年

強直性脊椎炎治療の世界市場規模は2023年に31億米ドルと評価され、2024年の33億4,000万米ドルから2032年には60億9,000万米ドルに拡大し、予測期間（2025～2032年）のCAGRは7.8％で成長する展望です。

特に若年・中年成人の強直性脊椎炎（AS）有病率の上昇が市場拡大に大きく影響しています。脊椎や仙腸関節に深刻な影響を及ぼす自己免疫性の慢性疾患であるASは、HLA-B27遺伝子のような遺伝的要因が主要原因であり、特に欧州、北米、アジアの一部などの地域で流行しています。認知度と診断能力が向上するにつれて、早期診断による長期的な管理と革新的な治療に対する需要が高まっています。生物学的療法、特に腫瘍壊死因子（TNF）阻害剤とインターロイキン-17（IL-17）遮断剤は、炎症経路を特異的に標的とする能力により、好ましい選択となりつつあります。現在進行中の研究開発は、次世代の生物製剤の開発を目指しており、治療選択肢における生物製剤の重要な役割を強化し、市場の成長を促しています。

目次

イントロダクション

• 調査の目的
• 調査範囲
• 定義

調査手法

• 情報調達
• 二次と一次データの方法
• 市場規模予測
• 市場の前提条件と制限

エグゼクティブサマリー

• 世界市場の展望
• 供給と需要の動向分析
• セグメント別機会分析

市場力学と展望

• 市場概要
• 市場規模
• 市場力学
  • 促進要因と機会
  • 抑制要因と課題
• ポーターの分析

主要市場の考察

• 重要成功要因
• 競合の程度
• 主要投資機会
• 市場エコシステム
• 市場の魅力指数（2024年）
• PESTEL分析
• マクロ経済指標
• バリューチェーン分析
• 価格分析
• 規制情勢
• 使用事例
• 技術分析

強直性脊椎炎治療市場規模：治療タイプ別&CAGR（2025～2032年）

• 市場概要
• NSAID（非ステロイド性抗炎症薬）
• 生物製剤（TNF阻害剤、IL-17阻害剤）
• DMARD（疾患修飾抗リウマチ薬）
• 理学療法と運動
• その他

強直性脊椎炎治療市場規模：薬剤タイプ別&CAGR（2025～2032年）

• 市場概要
• ブランド医薬品
• ジェネリック医薬品

強直性脊椎炎治療市場規模：エンドユーザー別&CAGR（2025～2032年）

• 市場概要
• 病院とクリニック
• 専門クリニック
• 在宅医療

強直性脊椎炎治療市場規模&CAGR（2025～2032年）

• 北米
  • 米国
  • カナダ
• 欧州
  • ドイツ
  • スペイン
  • フランス
  • 英国
  • イタリア
  • その他の欧州
• アジア太平洋
  • 中国
  • インド
  • 日本
  • 韓国
  • その他のアジア太平洋
• ラテンアメリカ
  • ブラジル
  • その他のラテンアメリカ
• 中東・アフリカ
  • GCC諸国
  • 南アフリカ
  • その他の中東・アフリカ

競合情報

• 上位5社の比較
• 主要企業の市場ポジショニング（2024年）
• 主要市場企業が採用した戦略
• 最近の市場動向
• 企業の市場シェア分析（2024年）
• 主要企業の企業プロファイル
  • 企業の詳細
  • 製品ポートフォリオ分析
  • 企業のセグメント別シェア分析
  • 収益の前年比比較（2022～2024年）

    主要企業プロファイル

    • AbbVie Inc.（米国）
    • Novartis AG（スイス）
    • Johnson & Johnson（米国）
    • Pfizer Inc.（米国）
    • Amgen Inc.（米国）
    • UCB S.A.（ベルギー）
    • Bristol-Myers Squibb（米国）
    • Eli Lilly and Company（米国）
    • Roche Holding AG（スイス）
    • Merck & Co., Inc.（米国）
    • Biogen Inc.（米国）
    • Celgene Corporation（米国）
    • Takeda Pharmaceutical Company Limited（日本）
    • Bayer AG（ドイツ）
    • Regeneron Pharmaceuticals（米国）
    • Teva Pharmaceutical Industries Ltd.（イスラエル）
    • Sandoz International GmbH（スイス）
    • Lupin Limited（インド）
    • Mylan N.V.（米国）

結論と提言

Global Ankylosing Spondylitis Treatment Market size was valued at USD 3.1 billion in 2023 and is poised to grow from USD 3.34 billion in 2024 to USD 6.09 billion by 2032, growing at a CAGR of 7.8% during the forecast period (2025-2032).

The rising prevalence of ankylosing spondylitis (AS), particularly among young and middle-aged adults, is significantly influencing market expansion. AS, an autoimmune chronic disorder that severely impacts the spine and sacroiliac joints, is predominantly driven by genetic factors such as the HLA-B27 gene, especially prevalent in regions like Europe, North America, and parts of Asia. As awareness and diagnostic capabilities improve, earlier diagnoses lead to an increased demand for long-term management and innovative treatments. Biologic therapies, notably tumor necrosis factor (TNF) inhibitors and interleukin-17 (IL-17) blockers, are becoming the preferred choice due to their ability to specifically target inflammation pathways. Ongoing research aims to develop next-generation biologics, reinforcing their critical role in therapeutic options and catalyzing market growth.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Ankylosing Spondylitis Treatment market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Ankylosing Spondylitis Treatment Market Segments Analysis

Global Ankylosing Spondylitis Treatment Market is segmented by Treatment Type, Drug Type, End-User and region. Based on Treatment Type, the market is segmented into NSAIDs (Non-Steroidal Anti-Inflammatory Drugs), Biologics (TNF Inhibitors, IL-17 Inhibitors), DMARDs (Disease-Modifying Anti-Rheumatic Drugs), Physical Therapy & Exercise and Others. Based on Drug Type, the market is segmented into Branded Drugs and Generic Drugs. Based on End-User, the market is segmented into Hospitals & Clinics, Specialty Clinics and Home Care. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Ankylosing Spondylitis Treatment Market

The rising global incidence of ankylosing spondylitis, especially in younger demographics, serves as a significant catalyst for the market. As more individuals receive a diagnosis, there is a growing need for effective treatment options. In response to this surge in therapeutic requirements, healthcare systems and pharmaceutical companies are dedicating increased resources to the development of innovative drugs, advanced diagnostic tools, and patient-centered care approaches. This trend highlights the urgency to meet the evolving needs of patients suffering from ankylosing spondylitis, further stimulating market growth and fostering advancements in treatment solutions.

Restraints in the Global Ankylosing Spondylitis Treatment Market

The Global Ankylosing Spondylitis Treatment market faces significant restraints, particularly in emerging markets where a lack of general practitioner awareness and low patient knowledge lead to delayed diagnoses of this condition. Such delays can result in advanced disease progression and reduced effectiveness of treatment options. Furthermore, the shortage of skilled rheumatologists and the absence of comprehensive initial screening programs exacerbate these challenges, ultimately hindering overall market growth. Addressing these barriers is essential to enhance early detection and ensure optimal management of ankylosing spondylitis, thereby improving patient outcomes and stimulating market development.

Market Trends of the Global Ankylosing Spondylitis Treatment Market

The Global Ankylosing Spondylitis Treatment market is witnessing a significant trend towards biologics, particularly TNF and IL-17 inhibitors, which are redefining therapeutic approaches due to their targeted mechanisms and improved efficacy. This shift is propelled by robust ongoing research and development, coupled with the expansion of biosimilar options, making these advanced therapies more accessible and cost-effective. As healthcare providers and patients seek long-term disease control and enhanced quality of life, the preference for biologic treatments continues to solidify, stimulating market growth. This transition underscores the evolving landscape of ankylosing spondylitis management and underscores the importance of innovation in therapeutic regimens.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Regulatory Landscape
• Case Studies
• Technological Analysis

Global Ankylosing Spondylitis Treatment Market Size by Treatment Type & CAGR (2025-2032)

• Market Overview
• NSAIDs (Non-Steroidal Anti-Inflammatory Drugs)
• Biologics (TNF Inhibitors, IL-17 Inhibitors)
• DMARDs (Disease-Modifying Anti-Rheumatic Drugs)
• Physical Therapy & Exercise
• Others

Global Ankylosing Spondylitis Treatment Market Size by Drug Type & CAGR (2025-2032)

• Market Overview
• Branded Drugs
• Generic Drugs

Global Ankylosing Spondylitis Treatment Market Size by End-User & CAGR (2025-2032)

• Market Overview
• Hospitals & Clinics
• Specialty Clinics
• Home Care

Global Ankylosing Spondylitis Treatment Market Size & CAGR (2025-2032)

• North America (Treatment Type, Drug Type, End-User)
  • US
  • Canada
• Europe (Treatment Type, Drug Type, End-User)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Treatment Type, Drug Type, End-User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Treatment Type, Drug Type, End-User)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Treatment Type, Drug Type, End-User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• AbbVie Inc. (U.S.)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson (U.S.)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc. (U.S.)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Amgen Inc. (U.S.)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• UCB S.A. (Belgium)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol-Myers Squibb (U.S.)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly and Company (U.S.)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Roche Holding AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co., Inc. (U.S.)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Biogen Inc. (U.S.)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Celgene Corporation (U.S.)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takeda Pharmaceutical Company Limited (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bayer AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Regeneron Pharmaceuticals (U.S.)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teva Pharmaceutical Industries Ltd. (Israel)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sandoz International GmbH (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Lupin Limited (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Mylan N.V. (U.S.)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations